Precede Biosciences, a Boston, MA-based biotechnology company providing a blood-based approach to revealing disease-defining transcriptional biology, emerged from stealth with $57M in funding since inception.
Precede was co-founded through the 4:59 Initiative at 5AM Ventures and supported in the seed round by both 5AM Ventures and Binney Street Capital of the Dana-Farber Cancer Institute. The company’s Series A financing was co-led by 5AM Ventures and Lilly Asia Ventures, who were joined by Illumina Ventures, Bristol Myers Squibb, Osage University Partners, and Qatar Investment Authority (QIA).
The company intends to use the funds to expand operations and its R&D efforts.
Led by CEO Rehan Verjee, and Chief Scientific Officer Carl Barrett, Ph.D., Precede provides a genome-wide platform that simultaneously explores the dynamic, feature-rich space of gene promoters, gene enhancers, and the DNA methylome from a single milliliter (1mL) of plasma. It is actively partnering with drug developers to accelerate the development of precision medicines by identifying the biology associated with response and resistance to treatment and by identifying targets mechanistically linked to disease biology. In parallel, the company is developing blood-based clinical tests to advance precision use of cancer medicines in clinical practice. Its platform is available to drug developers and academic researchers as a Research Use Only (RUO) platform as of today.
FinSMEs
09/10/2023